764 filings
Page 4 of 39
10-Q/A
2022 Q1
OGEN
Oragenics Inc
14 Apr 23
Quarterly report (amended)
3:46pm
8-K
OGEN
Oragenics Inc
10 Apr 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:44pm
8-K
OGEN
Oragenics Inc
3 Apr 23
Regulation FD Disclosure
8:30am
NT 10-K
OGEN
Oragenics Inc
31 Mar 23
Notice of late annual filing
4:15pm
8-K
OGEN
Oragenics Inc
14 Mar 23
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
8:57am
4
Janet Huffman
8 Mar 23
ORAGENICS / Janet Huffman ownership change
4:31pm
3
OGEN
Oragenics Inc
8 Mar 23
ORAGENICS / Janet Huffman ownership change
4:29pm
8-K
OGEN
Oragenics Inc
8 Mar 23
Oragenics Appoints Janet Huffman as Chief Financial Officer
9:22am
8-K
OGEN
Oragenics Inc
1 Mar 23
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
8:35am
424B5
OGEN
Oragenics Inc
24 Feb 23
Prospectus supplement for primary offering
4:28pm
8-K
OGEN
Oragenics Inc
24 Feb 23
Entry into a Material Definitive Agreement
4:22pm
8-K
OGEN
Oragenics Inc
3 Feb 23
Other Events
8:47am
EFFECT
OGEN
Oragenics Inc
26 Jan 23
Notice of effectiveness
12:15am
8-K
OGEN
Oragenics Inc
23 Jan 23
Material Modifications to Rights of Security Holders
4:05pm
CORRESP
OGEN
Oragenics Inc
23 Jan 23
Correspondence with SEC
12:00am
UPLOAD
OGEN
Oragenics Inc
19 Jan 23
Letter from SEC
12:00am
S-3
OGEN
Oragenics Inc
Shelf registration
13 Jan 23
4:21pm
4
Robert C Koski
3 Jan 23
ORAGENICS / ROBERT C KOSKI ownership change
4:20pm
8-K
OGEN
Oragenics Inc
23 Dec 22
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
4:19pm
8-K
OGEN
Oragenics Inc
22 Dec 22
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
9:00am